Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Transl Med. 2012 Dec 11;10:248. doi: 10.1186/1479-5876-10-248.

JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.

Author information

  • 1Don C, Gnocchi Foundation, ONLUS, Milan, Italy. rmancuso@dongnocchi.it

Abstract

BACKGROUND:

The use of natalizumab in multiple sclerosis (MS) may favour JC virus reactivation; this phenomenon is usually asymptomatic but can, albeit rarely, evolve into frank progressive multifocal leucoencephalopathy (PML).

METHODS:

JCV-specific CD8+ T lymphocytes were evaluated by flow cytometry over a 24-month period in 24 natalizumab-treated MS patients in whom JCV DNA was or was not detected in blood using quantitative real-time polymerase chain reaction; all these cases were asymptomatic.

RESULTS:

Perforin- and grazymes-containing VP-1-specific CD8+ T lymphocytes were reduced whereas CD107a-expressing cells were increased in JCV positive patients, suggesting an active degranulation of these cells; naïve CD8+ T lymphocytes were also decreased whereas memory cells were increased in patients in whom JCV reactivation was observed.

CONCLUSION:

The presence of a CD8+ T lymphocyte-mediated effector immune response offers a greater insight into reactivation of JCV and its clinical sequelae, and may help the monitoring of patients on natalizumab therapy.

PMID:
23232085
[PubMed - indexed for MEDLINE]
PMCID:
PMC3558446
Free PMC Article

Images from this publication.See all images (4)Free text

Figure 1
Figure 2
Figure 3
Figure 4
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk